Drug-eluting stents articles

ATC guiada por iFR ¿es igual en la DA que en el resto de los vasos?

LIFE-BTK | Critical Limb Ischemia: Use of Bioresorbable Scaffold in Infrapatellar Lesions (LIFE-BTK)

LIFE-BTK | Critical Limb Ischemia: Use of Bioresorbable Scaffold in Infrapatellar Lesions (LIFE-BTK)

Advanced stages of peripheral artery disease cause significant limitations in patients, such as critical limb ischemia (CLI), which manifests with resting pain and gangrene or ulcers of difficult resolution. Uncontrolled progression of this pathology might lead to major amputation, reduced life expectancy and increased healthcare costs.  Prior research on infrapopliteal territory have shown contradicting results.

Outcomes of the Use of Drug Coated Balloons in the Treatment of De Novo Coronary Lesions

Drug coated balloon (DCB) angioplasty offers a novel strategy for treating coronary artery disease. Studies assessing this strategy have shown clinical outcomes comparable to drug-eluting stents’ (DES) in patients with in-stent restenosis and de novo disease in small vessels. However, evidence for the use of DCB in large coronary vessels is limited. This observational, retrospective study DCB

ATC guiada por iFR ¿es igual en la DA que en el resto de los vasos?

iFR Guided PCI to the LAD: Same as for non-LAD Vessels?

iFR has been validated as a useful tool for intermediate lesion analysis, with the advantage of not requiring the use of drugs. On the other hand, its use for PCI outcome assessment has not yet been thoroughly looked into, even though there have been promising data.  24% of DEFINE PCI cases presented ≤0.89 iFR with

¿Es la litotricia coronaria tan efectiva como la aterectomía rotacional?

ROTACUT Study: Rotational Atherectomy with Cutting Balloon for Stent Expansion Optimization

Approximately 30% of patients undergoing percutaneous coronary intervention (PCI) present moderate to severe calcified lesions, which presents a significant challenge involving a high incidence of major adverse cardiovascular events (MACE). Rotational atherectomy (RA) is used to modify these calcified lesions and facilitate balloon angioplasty followed by stent implantation. The combination of RA with other plaque

Drug-Coated Balloons (DCB): Sirolimus vs. Paclitaxel in De Novo Lesions in Small Vessels

The use of drug-coated balloons (DCB) offers the advantage of avoiding permanent stent implants, thus reducing the incidence of in-stent restenosis (ISR), neoatherosclerosis, and late in-stent thrombosis. Additionally, the use of DCB reduces the duration of dual antiplatelet therapy. Current evidence supports the use of DCB for ISR treatment (Class I) compared with drug-eluting stents

¿Debemos utilizar balones liberadores de droga en pacientes con enfermedad de múltiples vasos?

Stentless Strategy in ACS: Perfusion and Drug Coated Balloons

The initial strategy for the treatment of patients at high risk of bleeding (HBR) after percutaneous coronary intervention (PCI) has consisted of a short dual antiaggregation therapy (DAPT). Stents continue to improve, which has allowed the reduction of DAPT schemes and therefore the incidence of bleeding.  However, researchers are also looking into another strategy to

Nuevas estrategias en el territorio femoropoplíteo

Low vs High Dose Drug Coated Balloons in Femoropopliteal Territory

The use of drub coated balloons (DCB) in the treatment of femoropopliteal artery disease has grown. Studies on first generation high dose DCB (HD-DCB) have shown benefits, which has led to their recommendation by current guidelines. However, there have been reports of secondary effects caused by paclitaxel and its excipients.  Second generation low dose DCB

By pass y actividad de la enfermedad en la arteria coronaria nativa

Long-Term Results from the BEST Study: Drug-Eluting Stents vs. Bypass Surgery in Diabetic Patients with Multiple Vessel Disease

The impact of diabetes on the development of cardiovascular disease is widely known, with a strong association with extensive and diffuse coronary artery disease. Decision-making regarding how to revascularize patients with multi-vessel disease is a complex process. In this context, coronary artery bypass grafting (CABG) has been recommended over percutaneous coronary intervention (PCI) based on

TCT 2023 | ALIGN AR trial

TCT 2023 | In Stent Restenosis: Sirolimus vs. Paclitaxel Coated Balloons

This was a prospective, multicenter, randomized study including 130 patients with instent restenosis treated with sirolimus coated balloons (DCB S) and 128 treated with paclitaxel coated balloons (DCB P).  Primary end point was late lumen loss (LLL) at 12 months.  There were no significant differences between the groups. Mean patient age was 63, 75% were

Resultados del estudio COMPARE a 2 años: Balones cubiertos de Paclitaxel con bajas dosis vs altas dosis

Ultrathin Stents Shown Safe and Effective in Real World Patients

Ultrathin drug eluting stents (60 µm) had been shown beneficial vs. thin-strut stents in terms of target lesion failure (TLF) at 2, 3 and 5 years in randomized studies, but they had not been yet assessed in “real world” patients.  The BIOFLOW VII is a prospective, multicenter study including 556 “real world”patients with a total

Top